The Laws of the Pharmaceutical Industry

[vootoodoo]

The main principles governing the pharmaceutical “business with disease.” It is not in the financial interests of the pharmaceutical industry to prevent common diseases – the maintenance and expansion of diseases is a precondition for the financial growth of this industry.

http://www4.dr-rath-foundation.org/PHARMACEUTICAL_BUSINESS/laws_of_the_pharmaceutical_industry.htm

[stef2011]

there are two one in london and one in malta so there are no customs in any european community country, they deliver by 3 days and prices are of course much lower than brand drugs.
in italy we hve free drugs by healthcare system but as in romania some are not approved yet like combo entecavir+tenofovir if there is no resistant mutants (pretty stupid, the main reason is prevent them) or interferon+tenofovir or interferon+entecavir
the only way to get these combo covered by healthcare is by the trials

it would be wonderful if we could get generic interferons....a couple of years yet

http://www.eurodrugstore.eu/

in italy you can but only vitamins and antioxidants online

[4est]

have no idea, but i think that a Europa law for free movement of the drugs have to exist.

I don't know if we can buy generics, maybe we can buy from webpage, but i don;t know the law (if it is allowed ... ).

good to know about the malta pharmacy if will be needed in future.

[stef2011]

really crazy but we also have some crazy laws in italy that noboy knows about or follow......

is it allowed to buy generics from india there?there is a pharmacy in malta that sells cheap generics from india and ships to EC

as regards italy there are crazy laws nobody knows about that you can t buy drugs in other EU states because we have the highest prices on drugs in europe, so they did this law to keep hi prices.we had a party who made war to drug makers about 4 years ago but they didn t approve online pahrmacies and all type of drugs sold in big malls/supermarkets

on the other hand there is a european law that says there is free movment of drugs within EC and any drug approved in any EC state can be used in the other states

[4est]

btw Tenofovir is not on the market also in Romania, even if we are in UE. Last approval drug for HBV was 2 year ago entecavir.
Is true that you can use Tenofovir, but no doctor will prescribe this because is not in the treatment guideline and the cost is not deductible ....

[stef2011]

i was like you once, after the swine flu fraud i can believe anything bad from them

drug makers know for sure of course, doctors are just ignorant because few of them double check guidelines and really understands what is behind or have the tools.
researchers have the advantage to study and check everything so they are aware and advized

how can you think possible tenofovir is not on market in china since 2000 like in the rest of the world?how can they treat with lam, telbivudine and adv?as you can see the oldest drug tenofovir, the only one which has no resistance, has been kept out of the market.....

[4est]

maybe you are right, maybe you are not I don't know and I do believe what you say in the above post, but is hard for me to accept this. I can accept that in Chine they have difficulty and not enough money for tenofovir, I can accept that the doctors are ignorant, i can accept they don't know the products, ...., but I can't accept that they do it with knowledge (interntionately) (or maybe I refuse to accept).  

[stef2011]

after all tenofovir was approved in 2000 for hiv and also lam was...do you think they put that on market and dont have all in vitro and animal studies on these drugs?do you think they dont have the data on potency?

[stef2011]

if you go back on this forum you will find a hepatitis researchers warning in the lam era 2000 to use tenofovir off label because it was known about the lam and adv danger

i was also saved by a scientist who work in US but still ahve a team here, they said already in 2000 that lam was useless due to the mutants....

it was intentional in the western countries between 2000 and 2005 and "IT is clearly Intentional now in china"

i do believe they got much more mutants in china because there is no possibility of using tenofovir while it was available off label in western countries

if you follow the tenofovir story it was approved 2008 in europe because off label use is totally free/easy here and there was so much data and studies to use it especially because the lam mutants couldnt be stopped

US was forced to approve it but it took one year to see it approved in US

[4est]

"anyway they have started trying to make the virus more aggressive by use of lam and adv and mutations so that patients are forced on nucs" - I can't believe that, even if is possible i can't believe that somebody will make mutation intentional in order to start a epidermic that can be controlled. and all of this only for some possible profit.

[stef2011]

i am afraid that they are trying to turn hbv in to another big seller like it was for hiv.....and all patents expire on nucs is another big problem for them

i wish europe was like india to ban US crazy patents....stem cell, gcmaf and bio-drugs will all be a big problem for US drug makers

[stef2011]

you have also to consider they are afraid of losing the hiv market because the lies behind the epidemy that never happened or aids deaths which are very low on people not taking antivirals is coming

all nobels, even montagner the discoverer, has said hiv and aids are not correlated.i am afraid that they are trying to turn hbv in to another big seller like it was for hbv...but it is not easy because hbv doesn t make liver damage on all bt only on a minority...anyway they have started trying to make the virus more aggressive by use of lam and adv and mutations so that patients are forced on nucs

[4est]

i understand your point.

also new tenofovir GS-7340 it is like old one but only change the delivery protein and make it more powerful and less toxic.

in this moment the NUC's are on the power and all predictions are made (build) on the actual market and on the actual price ... all new drugs are price based on the actual treatment prices.
And they don't discuss any cure, because on this moment nobody announce any significant result for a cure, the closeted one are REP9AC and MYR but are on the beginning and they work on a small number of patients and the percentage are 50% for cure - similar procent looks like it can be achieved also by a NUC / INF combo, so no big danger for NUC providers.

On the other hand INF lambda is on the way to market and look like is more powerful then the actual one so the NOC / INF combo can do better.

[stef2011]

they are just trying to keep it patented, tenofovir in asia has so many generics that they were forced to sell it 7USd per month.

they just could make corruption so that tenofovir cannot enter chinese market, tenofovir is not available in china because they need to sell the useless lam and adv.....they are jsut trying to get tenofovir there under a new name just to keep the price high.chinese people should buy tenofovir in india and not in china from generics company and ruin this MF market

it is disgusting the way they make money by corruption

[vootoodoo]

My point was not in the new name, but in the way our problem is just statistics and profit for someone else. Looks like they have no doubts that even in 2019 their NUC is going to sell and even better than now...And btw the article does say it is the same as tenofovir plus a sidechain, whatever that means, but its still the same old s...t.

[4est]

look to me that AGX-1009 is not the new tenofovir, even if it share the same active substance.

New tenofovir is GS-7340 and is under GSK development and in clinical trials for hiv. GSK is expected to enter on chines market on 2014 with the actual tenofovir, anyway this AGX-1009 look interesting and we shoul look closer tho this also, after they start the trials (2012). (we have to found a good source of information about the china trials results)

[vootoodoo]

In case anyone has any illusions as to how things look from the other side, here is an extract of a pharma's chairman's address to shareholders at 2011 Annual General Meeting... Its simply a market, and its growing, expected to reach 1.3 billion in 2019 in China, therefore they come forward with their brand new version of Tenofovir, because "It is a huge market and Agenix is familiar with how it works."!!!!

"Lead drug AGX-1009 aims to help meet large unmet medical needs in China
.....
In 2009 it was estimated that the market for hepatitis B treatments in China (excluding Hong Kong, Macao and Taiwan) was $227.4 million in hospitals alone and $460 million across the whole market, with an annual growth rate of 31 per cent between 2008 and 2009, and a compound annual growth rate of 56 per cent between 2006 and 2009.

The Chinese hepatitis B drugs market grew by 31 per cent by volume between 2008 and 2009, with a 2006 - 2009 compound annual growth rate of 47 per cent.

The highest selling drug in China for hepatitis B was 'Adefovir' with sales of $109 million, although other drugs ' Lamivudine' and 'Entecavir' had sales of greater than $84 million.

Due to improved access to medication and a burgeoning middle class, Datamonitor forecasts that the hepatitis B drugs market in China will reach a total value of $701.5 million in 2019 in hospitals alone. IMS Health puts the overall market figure at $1.3 billion. It is a huge market and Agenix is familiar with how it works.

AGX-1009 is a patented tenofovir 'prodrug' with the same active compound as Gilead's FDAapproved tenofovir 'prodrug' Viread. It has the same active ingredient, tenofovir, but contains a different molecular sidechain that drops away as the drug nears its site of desired activity in the body.
......
We expect this is likely to play out the same way in China where GSK has the marketing rights to Viread and when it receives manufacturing and marketing approval from China's State Food and Drug Administration (SFDA) sometime likely to be in 2014.

Patients develop resistance to the major existing HBV medications over time and chronic HBV patients then need to change to a next generation therapy. In the case of lamivudine, around 80% of patients develop resistance after 5 years. In the case of adefovir, almost 30% of patients develop resistance after 5 years.

Agenix is positioned to offer very strong competition in this large medical market with our lead product candidate, AGX-1009, which belongs to the same class of drugs as Viread known as nucleotide analogue reverse transcriptase inhibitors. They work by blocking an enzyme the virus requires to replicate. AGX-1009 will be a once-a-day therapy for this market."


abnnewswire.net/press/en/70343/Agenix_Limited_(ASX:AGX)_Chairmans_Address_to_Shareholders_at_2011_Annual_General_Meeting.html